Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying biomarkers and therapeutic targets for COPD

ABSTRACT: Biological indicator and lung proteomics analyses were performed to identify potential therapeutic targets.

ORGANISM(S): Mus Musculus

SUBMITTER: Xishuai Wang

PROVIDER: PXD054322 | iProX | Sat Jul 27 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Application of the ISM bioinformatics platform in detection of new therapeutic targets and potential therapeutic molecules

Project description:Application of EIIP / ISM bioinformatics platform in detection of new therapeutic targets and potential therapeutic molecules. Study of the molecular basis of rare human diseases

2020-12-16 | PRJEB42044 | EVA

Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

Project description:Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

| PRJNA386152 | ENA

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Project description:Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

| PRJNA547577 | ENA

Supermeres, a new functional extracellular nanoparticle replete with disease biomarkers and therapeutic targets

Project description:Supermeres, a new functional extracellular nanoparticle replete with disease biomarkers and therapeutic targets

| PRJNA707335 | ENA

Supermeres, a new functional extracellular nanoparticle replete with disease biomarkers and therapeutic targets

Project description:Supermeres, a new functional extracellular nanoparticle replete with disease biomarkers and therapeutic targets

| PRJNA707327 | ENA

Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas

Project description:The proteomic and posttranslational modification signatures of most cancers are unknown. N-linked glycosylation is a post-translational modification that targets proteins for membrane expression or secretion making this class of proteins attractive cancer biomarkers and therapeutic targets. Using an unbiased mass spectrometry (MS)-based approach we generated a compendium of 1,155 N-linked glycoproteins (2,160 N-glycosites) from 44 human primary lymphomas and malignant lymphoma cell lines. Hierarchical clustering highlighted distinct subtype signatures which included several novel subtype-specific biomarkers. Orthogonal immunologic studies in 671 primary lymphoma tissue biopsies, 36 lymphoma-derived cell lines or 8 patient-derived circulating tumor cell samples corroborated MS-based glycoproteomic data and authenticated selected proteins as tissue biomarkers. Functional targeting using a toxin-conjugated ligand in vitro and RNAi-mediated silencing targeting subtype-specific glycoproteins abrogated lymphoma growth in vivo. Our results demonstrate the utility of global N-glycoproteomics discovery of cancer biomarkers and targets for precision therapeutics.

2017-06-19 | PXD003469 | Pride

Potential Therapeutic Targets for Donor Lung Repair During Human Ex Vivo Lung Perfusion Prior to Transplantation

Project description:Potential Therapeutic Targets for Donor Lung Repair During Human Ex Vivo Lung Perfusion Prior to Transplantation

| PRJNA524402 | ENA

Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis

Project description:Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis

| PRJNA604770 | ENA

MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets

Project description:MicroRNA (miRNA) expression profiles were generated from prostate epithelial sub-populations, enriched from patient-derived benign prostatic hyperplasia (BPH, n=5), Gleason 7 treatment naÃ¯ve prostate cancer (PCa, n=5) and castration-resistant prostate cancer (CRPC, n=3). Microarray expression was validated in an independent patient cohort (n=10). The analyses show that miRNA expression in epithelial sub-populations (e.g. stem cells) clustered together, irrespective of pathological status. We also discovered concordance between the miRNA expression profiles of unfractioned CRPCs, human embryonic stem cells (SCs), and prostate epithelial SCs (both, benign and malignant). miR-548c-3p was chosen as a candidate miRNA from this group to explore its utility as a CRPC biomarker and/or therapeutic target. Overexpression of miR-548c-3p was confirmed in cancer SCs (8-fold, p<0.05) and unfractionated CRPCs (1.8-fold, p<0.05). Enforced overexpression of miR-548c-3p in differentiated cells induced stem-like properties (p 0.01) and radioresistance (p<0.01). Re-analyses of published studies further revealed that miR-548c-3p is significantly overexpressed in CRPC (p<0.05) and is associated with poor recurrence-free survival (p<0.05), suggesting that miR-548c-3p is a functional biomarker for prostate cancer aggressiveness. Our results validate the prognostic and therapeutic relevance of miRNAs for advanced prostate cancer management, whilst demonstrating that resolving cell-type and differentiation-specific differences is essential to obtain clinical relevant miRNA expression profiles. There are 42 samples in total: 15 benign prostatic hyperplasia, 15 prostate cancers, 9 treatment-resistant prostate cancer. There are stem cells, transit amplifying cells and committed basal cells dissected from each sample. Three PrEC samples of each three cell types can be used as reference.

2016-07-03 | E-GEOD-59156 | biostudies-arrayexpress

The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

Project description:The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

| PRJNA785165 | ENA